Non-medical use of olanzapine by people on methadone treatment
... is also growing evidence that olanzapine is effective in the treatment of individuals with schizophrenia and a co-occurring substance use disorder.18 Similarly, there is evidence that quetiapine may also be effective specifically in helping those with substance use disorders.19,20 There are also stud ...
... is also growing evidence that olanzapine is effective in the treatment of individuals with schizophrenia and a co-occurring substance use disorder.18 Similarly, there is evidence that quetiapine may also be effective specifically in helping those with substance use disorders.19,20 There are also stud ...
Jeopardy Template
... Do you hear... for 400 • Effects on this receptor, which include dry mouth and constipation, are more common with olanzapine than risperidone • What is muscarinic (cholinergic)? ...
... Do you hear... for 400 • Effects on this receptor, which include dry mouth and constipation, are more common with olanzapine than risperidone • What is muscarinic (cholinergic)? ...
Psychopharmacology - the Peninsula MRCPsych Course
... Effects of prolactin - galacttorhoea, breast development, amenorrhoea Lower seizure threshold Effect on temperature control Agranulocytosis ...
... Effects of prolactin - galacttorhoea, breast development, amenorrhoea Lower seizure threshold Effect on temperature control Agranulocytosis ...
Click here for handout
... The incidence of clinically significant weight gain with aripiprazole and ziprasidone is considerably less than that with olanzapine, hence the risk of developing metabolic syndrome with these 2 agents is comparable to placebo. ...
... The incidence of clinically significant weight gain with aripiprazole and ziprasidone is considerably less than that with olanzapine, hence the risk of developing metabolic syndrome with these 2 agents is comparable to placebo. ...
Secondary Stroke Prevention: Implications of the MATCH Trial
... patients with >10% initial body weight gain, length of weight gain, types of weight gain) Risk of significant weight gain: – Clozapine, olanzapine and quetiapine, high – Risperidone, moderate – Ziprasidone, aripiprazole, low Generally, thinner people gain more weight (lower BMI) • weight gain se ...
... patients with >10% initial body weight gain, length of weight gain, types of weight gain) Risk of significant weight gain: – Clozapine, olanzapine and quetiapine, high – Risperidone, moderate – Ziprasidone, aripiprazole, low Generally, thinner people gain more weight (lower BMI) • weight gain se ...
Jeopardy
... Even though it is most efficacious antipsychotic, this drug is not considered for first line use due to its side effect profile ...
... Even though it is most efficacious antipsychotic, this drug is not considered for first line use due to its side effect profile ...
Schizophrenia II - Psychiatry Training
... – Prolactin elevation and extrapyramidal side effects (EPS) were characteristic side effect (e.g. haloperidol) – EPS: parkinsonism, akathisia, dystonia; were thought to be inextricably linked with antipsychotic efficacy ...
... – Prolactin elevation and extrapyramidal side effects (EPS) were characteristic side effect (e.g. haloperidol) – EPS: parkinsonism, akathisia, dystonia; were thought to be inextricably linked with antipsychotic efficacy ...
Jeopardy - lumen.luc.edu
... Even though its the most efficacious antipsychotic, its side effect profile prevents this drug from consideration for first line use ...
... Even though its the most efficacious antipsychotic, its side effect profile prevents this drug from consideration for first line use ...
Slide 1
... Depression with psychotic features vs. psychotic symptoms of dementia SSRIs used most often due to favorable side effect profile Five trials showed no efficacy for treating neuropsychiatric symptoms other than depression, with the exception of 1 study of citalopram. ...
... Depression with psychotic features vs. psychotic symptoms of dementia SSRIs used most often due to favorable side effect profile Five trials showed no efficacy for treating neuropsychiatric symptoms other than depression, with the exception of 1 study of citalopram. ...
Pharmacology—Antipsychotic Drug Therapy
... for a slow release of the drug over a period of several weeks. Plasma concentrations increase slowly three weeks after injection and peak at about four to six weeks. Usually dose is 25mg deep IM q2 weeks. Max dose is 50mg q2 weeks. Doses should be increased no more frequently than every four weeks. ...
... for a slow release of the drug over a period of several weeks. Plasma concentrations increase slowly three weeks after injection and peak at about four to six weeks. Usually dose is 25mg deep IM q2 weeks. Max dose is 50mg q2 weeks. Doses should be increased no more frequently than every four weeks. ...
OLANZapine (oh-lan-za-peen) - DavisPlus
... skin. Use only diluent provided by manufacturer. Dilute 150 mg or 210 mg dose with 1.3 mL, 300 mg with 1.8 mL and 405 mg with 2.3 mL of diluent. Loosen powder by tapping vial; inject diluent into powder. Remove needle from vial holding vial upright to prevent loss of solution. Engage needle safety d ...
... skin. Use only diluent provided by manufacturer. Dilute 150 mg or 210 mg dose with 1.3 mL, 300 mg with 1.8 mL and 405 mg with 2.3 mL of diluent. Loosen powder by tapping vial; inject diluent into powder. Remove needle from vial holding vial upright to prevent loss of solution. Engage needle safety d ...
Antipsychotics - 2011
... respond in the first 1-2 weeks Personal hygiene and basic interpersonal socialisation may take 2-3 weeks and psychotic symptoms can gradually decrease over 2-6 weeks An effective trial should be at least 6-8 weeks at doses that are within the prescribed range ...
... respond in the first 1-2 weeks Personal hygiene and basic interpersonal socialisation may take 2-3 weeks and psychotic symptoms can gradually decrease over 2-6 weeks An effective trial should be at least 6-8 weeks at doses that are within the prescribed range ...
6 points each
... 9. Dry mouth is a major side effect of olanzapine in many patients. Orthostatic hypotension is also seen in some patients. Theoretically, what kinds of change(s) in receptor binding would be desirable in a new drug (call it “neo-olanzapine”) that would have the same therapeutic effect and potency as ...
... 9. Dry mouth is a major side effect of olanzapine in many patients. Orthostatic hypotension is also seen in some patients. Theoretically, what kinds of change(s) in receptor binding would be desirable in a new drug (call it “neo-olanzapine”) that would have the same therapeutic effect and potency as ...
Psychosis 2016
... clozapine for treatment-resistant patients) SGAs have a small but significant effect size superiority in the treatment of negative symptoms and cognitive impairment Tx resistance 20% multiple episode pts have NO positive symptom response to AP 30% respond partially Tx refractoriness= failed trials o ...
... clozapine for treatment-resistant patients) SGAs have a small but significant effect size superiority in the treatment of negative symptoms and cognitive impairment Tx resistance 20% multiple episode pts have NO positive symptom response to AP 30% respond partially Tx refractoriness= failed trials o ...
Use of Atypical Antipsychotic Agents for Symptom Control in Patients
... In contrast to conventional antipsychotic agents, the atypical antipsychotics (also called second-generation antipsychotics) are agents that have been available only since the early 1990s. These drugs include risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon), ...
... In contrast to conventional antipsychotic agents, the atypical antipsychotics (also called second-generation antipsychotics) are agents that have been available only since the early 1990s. These drugs include risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon), ...
Important side effects to be considered when choosing antipsychotic
... Dopamine receptor blocking activity in the brain:. D1 and D5 receptors activate adenylyl cyclase, often exciting neurons, whereas D2, D3 and D4 receptors inhibit adenylyl cyclase, or mediate membrane K+ channel opening leading to neuronal hyperpolarization. The neuroleptic drugs bind to these rece ...
... Dopamine receptor blocking activity in the brain:. D1 and D5 receptors activate adenylyl cyclase, often exciting neurons, whereas D2, D3 and D4 receptors inhibit adenylyl cyclase, or mediate membrane K+ channel opening leading to neuronal hyperpolarization. The neuroleptic drugs bind to these rece ...
Programme of the 29th ECNP Congress
... enzymes in the serum of chronically medicated schizophrenic patients regardless of their treatment type. However, in the case of the atypical antipsychotics the oxidative stress could be an indicator of illness severity, since quetiapine and olanzapine are formally indicated for a speci c group of s ...
... enzymes in the serum of chronically medicated schizophrenic patients regardless of their treatment type. However, in the case of the atypical antipsychotics the oxidative stress could be an indicator of illness severity, since quetiapine and olanzapine are formally indicated for a speci c group of s ...
The Atypical Antipsychotics
... atypical agents are serotonin-dopamine 2 antagonists (SDAs) They are considered atypical in the way they affect dopamine and serotonin neurotransmission in the four key dopamine pathways in the brain. Mechanism of action Dopamine receptor blocking activity in the brain:. D1 and D5 receptors activate ...
... atypical agents are serotonin-dopamine 2 antagonists (SDAs) They are considered atypical in the way they affect dopamine and serotonin neurotransmission in the four key dopamine pathways in the brain. Mechanism of action Dopamine receptor blocking activity in the brain:. D1 and D5 receptors activate ...
Pharmacological Managment of Treatment Resistant
... - Cloza > OLZ on suicidal behaviors (Intersept: Meltzer et al., 2003) - „ pro-cognitive “ effects of OLZ > cloza (anticholinergic properties). - Tolerance: a limitation of its use (weight, metabolic disturbances, agranulocytosis, sedation). ...
... - Cloza > OLZ on suicidal behaviors (Intersept: Meltzer et al., 2003) - „ pro-cognitive “ effects of OLZ > cloza (anticholinergic properties). - Tolerance: a limitation of its use (weight, metabolic disturbances, agranulocytosis, sedation). ...
powerpoint presentation for teaching
... • Increased creatine phosphokinase and leukocytes • More common in first weeks of treatment • Increased risk with higher doses, multiple drugs, male, and young • Can lead to loss of consciousness and death • Misdiagnosis: catatonia, EPS, serotonin syndrome, ...
... • Increased creatine phosphokinase and leukocytes • More common in first weeks of treatment • Increased risk with higher doses, multiple drugs, male, and young • Can lead to loss of consciousness and death • Misdiagnosis: catatonia, EPS, serotonin syndrome, ...
Use lowest possible doses – monitor for side effects
... increases in mortality in the drug-treated group compared to the placebo-treated patients – N = 5106 involving Risperidone (7 trials), Olanzapine (5 trials), Aripiprazole (3 trials) and Quetiapine (2 trials) – ~1.6-1.7 fold increase in mortality in active treatment over placebo ...
... increases in mortality in the drug-treated group compared to the placebo-treated patients – N = 5106 involving Risperidone (7 trials), Olanzapine (5 trials), Aripiprazole (3 trials) and Quetiapine (2 trials) – ~1.6-1.7 fold increase in mortality in active treatment over placebo ...
Psychosis
... Olanzapine Efficacy: +ve and –ve sx Tx resistant: Resperidone, Olanzapine and quetiapine ...
... Olanzapine Efficacy: +ve and –ve sx Tx resistant: Resperidone, Olanzapine and quetiapine ...
Gary Tollefson 1951-2009
... were all the more significant because they were carried out in a climate of (and in spite of) repeated attacks on our field by groups and individuals that reject the use of psychotropic medicines, even for the most severely ...
... were all the more significant because they were carried out in a climate of (and in spite of) repeated attacks on our field by groups and individuals that reject the use of psychotropic medicines, even for the most severely ...
Anglická výuka
... relapses with APs signif. lower than with placebo (circa 20% vs 50%) poor adherence leads to relapse and high costs to individuals, families, carers and society stopping medication is the most powerful predictor of relapse ...
... relapses with APs signif. lower than with placebo (circa 20% vs 50%) poor adherence leads to relapse and high costs to individuals, families, carers and society stopping medication is the most powerful predictor of relapse ...
Olanzapine
Olanzapine (originally branded Zyprexa) is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.Olanzapine is structurally similar to clozapine and quetiapine, but is classified as a thienobenzodiazepine. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company; the drug went generic in 2011. Sales of Zyprexa in 2008 were $2.2B in the US, and $4.7B worldwide.